$32.48
Cymabay Therapeu is a biotechnology business based in the US. Cymabay Therapeu shares (CBAY) are listed on the NASDAQ and all prices are listed in US Dollars. Cymabay Therapeu employs 101 staff and has a trailing 12-month revenue of around $31.1 million.
Our top picks for where to buy Cymabay Therapeu stock
How to buy Cymabay Therapeu stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CBAY. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Cymabay Therapeu stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Cymabay Therapeu stock price (NASDAQ: CBAY)
Use our graph to track the performance of CBAY stocks over time.Cymabay Therapeu shares at a glance
Latest market close | $32.48 |
---|---|
52-week range | $11.27 - $32.50 |
50-day moving average | $29.11 |
200-day moving average | $19.07 |
Wall St. target price | $32.50 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.99 |
Is it a good time to buy Cymabay Therapeu stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cymabay Therapeu price performance over time
Historical closes compared with the close of $32.48 from 2024-03-21
1 week (2024-07-13) | N/A |
---|---|
1 month (2024-06-20) | N/A |
3 months (2024-04-20) | N/A |
6 months (2024-01-24) | 42.14% |
1 year (2023-07-24) | 174.56% |
---|---|
2 years (2022-07-22) | 931.11% |
3 years (2021-07-23) | 686.44% |
5 years (2019-07-24) | 397.40% |
Cymabay Therapeu financials
Revenue TTM | $31.1 million |
---|---|
Gross profit TTM | $-41,635,000 |
Return on assets TTM | -22.05% |
Return on equity TTM | -64.17% |
Profit margin | 0% |
Book value | $2.57 |
Market Capitalization | $3.7 billion |
TTM: trailing 12 months
Cymabay Therapeu share dividends
We're not expecting Cymabay Therapeu to pay a dividend over the next 12 months.
Cymabay Therapeu share price volatility
Over the last 12 months, Cymabay Therapeu's shares have ranged in value from as little as $11.27 up to $32.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cymabay Therapeu's is 0.32. This would suggest that Cymabay Therapeu's shares are less volatile than average (for this exchange).
Cymabay Therapeu overview
CymaBay Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc.
Frequently asked questions
nullWhat percentage of Cymabay Therapeu is owned by insiders or institutions?
Currently 0.516% of Cymabay Therapeu shares are held by insiders and 103.125% by institutions. How many people work for Cymabay Therapeu?
Latest data suggests 101 work at Cymabay Therapeu. When does the fiscal year end for Cymabay Therapeu?
Cymabay Therapeu's fiscal year ends in December. Where is Cymabay Therapeu based?
Cymabay Therapeu's address is: 7601 Dumbarton Circle, Fremont, CA, United States, 94555 What is Cymabay Therapeu's ISIN number?
Cymabay Therapeu's international securities identification number is: US23257D1037 What is Cymabay Therapeu's CUSIP number?
Cymabay Therapeu's Committee on Uniform Securities Identification Procedures number is: 23257D103
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question